Gil Beyen is Chief Executive Officer and Chairman of ERYTECH Pharma. For ERYTECH, Gil Beyen has served as the Chief Executive Officer since May 2013 and Chairman of the board since 2012. Prior to his appointment as Chief Executive Officer, he assisted the company in a consulting role as of 2012 and also served as Chairman of the company’s supervisory board from August 2012 until May 2013.
Between 2000 and 2012, Mr. Beyen was Chief Executive Officer and Director of TiGenix, a company he co-founded. He previously served as the head of the life sciences practice of Arthur D. Little, an international management consulting firm, in Brussels. Mr. Beyen received an M.S. in bioengineering from the University of Leuven in Belgium and an MBA from the University of Chicago.
In this exclusive 2,136 word interview with the Wall Street Transcript, Gil Beyen details the unique way his company will create cancer treatments:
“Another unique property of red cells is that they will end their lives in the spleen, the liver and the bone marrow, within the reticulo-endothelial system. This makes it so that our technology can also be used to transform the red cell into a carrier of certain therapeutic agents to these organs. For example, we are using this in a preclinical program where we use the red cell for immunotherapy.
Here, we load antigens or adjuvants into the red cells, who will carry them — sort of like in a Trojan horse approach — to, for example, the dendritic cells in the spleen, where they activate cytotoxic T cells with demonstrated anti-tumor effect.”
The development of their therapy is well advanced:
“…With our lead product candidate, eryaspase, that has been administered to over 320 patients in different clinical trials, we have observed an improved safety profile compared to native, nonencapsulated asparaginase. ”
Get the complete detail by reading the complete 2,136 word interview with Gil Beyen, CEO and Chairman of ERYTECH Pharma.
Bernard Gilly, Ph.D, Co-Founder of GenSight Biologics Discusses the Proprietary Genetic Therapy Cure for Blindness his Company is Developing
October 23, 2018
Moleculin Biotech CEO Walter Klemp Wants to Advance this Cure for Cancer
October 15, 2018
Ovarian Cancer Cure from a Canadian Biotech Biovaxys? CEO James Passin Makes Bold Promise for H2 2022
March 28, 2022
Scott Wylie, Founder, Chairman and CEO of First Western Financial, Explains How to Start Up a Bank
February 26, 2019
